Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Investing in pension schemes can pay dividends for employers
I recently had the pleasure of speaking to a group of employers about workplace pensions and the value they can deliver, both for employees and for bu
Customer fairness is not a nice to have its your duty
While insurers understand their obligation to treat customers fairly, the harder question is how they demonstrate that they are doing so – particularl
3 numbers show human-in-the-loop cyber defence is outdated
How do you defend against AI attack speed? As cyberattacks become increasingly AI-driven, human-in-the-loop cyber defence is leaving organisations vul

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.